New chemotherapy options for the treatment of malignant gliomas.
Chemotherapy remains part of the treatment triad that includes surgery and radiation therapy for the management of malignant gliomas. In recent years there has been an increased understanding of the molecular pathways of malignant transformation. Based on this research, new drugs have been evaluated, with specific cellular targets in mind that can be modified or inhibited. Many of these agents are now being tested in phase I and II clinical trials and have shown some promising results. Clearly, not all patients with malignant gliomas respond equally to chemotherapy. Recent evidence suggests that certain molecular markers may predict chemosensitivity in some tumor types, particularly anaplastic oligodendroglioma. This article reviews recent trends in the use of chemotherapy and clinical trials of new therapies for adults with malignant gliomas.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077146:Irinotecan; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D009837:Oligodendroglioma / Q000188:drug therapy / Q000235:genetics; D011480:Protease Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology; D000077204:Temozolomide; D013792:Thalidomide / Q000627:therapeutic use